Jessica Serra | Head, IR and ESG |
Mark Foley | President and CEO |
Toby Schilke | CFO |
Dr. Abhay Joshi | COO and President, R&D and Product Operations |
Dustin Sjuts | Chief Commercial Officer, Aesthetics and Therapeutics |
Aubrey Rankin | President, Innovation and Technology |
Ken Cacciatore | Cowen & Company |
Seamus Fernandez | Guggenheim |
Terence Flynn | Goldman Sachs |
Annabel Samimy | Stifel |
Balaji Prasad | Barclays |
Tim Lugo | William Blair |
David Amsellem | Piper Sandler |
Chico Hughes | Wells Fargo Securities |
Vamil Divan | Mizuho Securities |
Serge Belanger | Needham & Company |
Chris Bialas | H.C. Wainwright |
Welcome to the Revance Therapeutics First Quarter 2021 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, May 10, 2021. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance please go ahead, ma’am.
Thank you, Donna.
Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr.